

1 **High-Density Lipoprotein (HDL) Subtypes Adversely Alter Brain Structure in** 2 **Mild Cognitive Impairment: A Tensor-Based Morphometry Analysis**

3
4
5 Running title: **HDL Subtypes and Brain Structure in MCI**

6
7
8 *Ali Azargoonjahromi*^{1*}, *Mitra Ashrafi*², *Donya Abroushan*³, *Elham Ramezannezhad*⁴,
9 *Mohammad Sadeghi*⁵, *Seyede Roxane Pooresmaeil Niaki*⁶, *Mehrsa Radmanesh*⁷, *Amin*
10 *Haratian*⁸, *Azin Taki*⁹, *Negar Nekahi*¹⁰, *Yeganeh Moshiri*¹¹, *Marzieh Rahimi*¹², *Heidar*
11 *Fadavian*¹³, *Seyede Maryam Mousavi*¹⁴, *Atousa Moghadam Fard*¹⁵, and *Mahsa Mayeli*¹⁶.

12
13
14 ¹ Shiraz University of Medical Sciences, Shiraz, Iran. aazargoonj@gmail.com ORCID: 0000-0002-6997-
15 9419

16 ² Zanjan University of Medical Sciences, Zanjan, Iran. Mitra.ashrafi.ma@gmail.com

17 ³ Islamic Azad University, Tehran Medical Branch, Tehran, Iran. donya.abroushan@gmail.com

18 ⁴ School of Medicine, Isfahan University of Medical Science, Isfahan, Iran. eramezannejad@gmail.com

19 ⁵ School of Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
20 Sadeghimohammad009@gmail.com

21 ⁶ Statistics and Applications, College of Science, University of Tehran, Tehran, Iran.
22 roxane.psn@gmail.com

23 ⁷ Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
24 mehrsa.radmanesh@gmail.com

25 ⁸ Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University,
26 Tehran, Iran. aamin.haratian@gmail.com

27 ⁹ Faculty of Medicine, Najafabad Branch, Islamic Azad University, Najafabad, Iran. azintt0@gmail.com

28 ¹⁰ Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran. Negarnekahi94@gmail.com

29 ¹¹ Faculty of Psychology and Educational Sciences, Central Tehran Branch, Islamic Azad University,
30 Tehran, Iran. Moshiri.yeg@gmail.com

31 ¹² Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
32 Rahimimr98@gmail.com

33 ¹³ Tarbiat Modares University, Tehran, Iran. heidarfadavian@gmail.com

34 ¹⁴ School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. marymousavi22@gmail.com

35 ¹⁵ Universal Scientific Education and Research Network, Tehran, Iran. Atoosa.mf74@gmail.com

36 ¹⁶ School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

37 mmayeli@som.umaryland.edu ORCID: 0000-0003-4656-156X

38

39

40

41 ***Corresponding Authors:**

42

43 1. Ali Azargoonjahromi

44 Shiraz University of Medical Sciences, Shiraz, Iran. aazargoonj@gmail.com ORCID: 0000-0002-6997-

45 9419

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61 **Abstract**

62 High-density lipoprotein (HDL) cholesterol is typically protective for cognitive function due to its anti-
63 inflammatory, antioxidant, and vascular health benefits. However, recent studies indicated that certain
64 HDL subtypes might be associated with adverse brain structural changes, commonly seen in mild
65 cognitive impairment (MCI). Thus, further research is needed to understand the intricate relationship
66 between HDL levels and brain structure, potentially leading to more effective therapeutic strategies. The
67 current study aimed to investigate the impact of HDL subtypes, such as XL_HDL_P, M_HDL_FC_PCT,
68 M_HDL_P, M_HDL_C, and M_HDL_CE, as well as APOA1, on brain structure in individuals with MCI
69 using tensor-based morphometry (TBM). The study analyzed ADNI data from subjects with at least two
70 serial MRI scans, processed using the Mayo TBM-Symmetric Normalization (SyN) pipeline and SyN for
71 longitudinal measures. The CDR and ADAS scores were used to assess the severity of cognitive
72 impairment and disease progression in our study participants. Significant ROIs were identified from a
73 Mayo Clinic training set, and TBM-SyN scores were computed. The significant correlation was
74 considered with p-values less than 0.05. The study found significant negative effects of several
75 lipoproteins on TBM scores in individuals with MCI. Specifically, XL_HDL_P, with an effect size of -
76 0.00145 (p=0.029), and M_HDL_FC_PCT, with an effect size of -0.00199 (p=0.0016), were linked to
77 lower TBM scores. Similarly, M_HDL_P (-0.00138, p=0.028), M_HDL_C (-0.00140, p=0.025),
78 M_HDL_CE (-0.00136, p=0.031), and APOA1 (-0.00149, p=0.017) also showed significant associations.
79 These findings indicate that higher levels of HDL subtype cholesterol are significantly associated with
80 reduced TBM scores, suggesting that elevated levels are linked to adverse structural brain changes, such
81 as atrophy, in individuals with MCI, potentially contributing to cognitive decline.

82 **Keywords:** High-density Lipoprotein; Cognitive Impairment; Lipoproteins; Brain Structure; Cholesterol;
83 Cognitive Function.

84

85

86

87

88

89

90

91 1. Introduction

92 High-density lipoprotein (HDL) is a type of lipoprotein that helps transport cholesterol from the
93 bloodstream and tissues back to the liver for excretion or reuse (1). Often referred to as “good”
94 cholesterol, HDL plays a key role in cardiovascular health by reducing the risk of atherosclerosis and
95 other heart-related diseases (2, 3). Structurally, HDL particles are composed of a core of cholesterol and
96 triglycerides encased in a layer of phospholipids and proteins, primarily apolipoprotein A-I (ApoA-I).
97 This structure enables HDL to efficiently transport cholesterol from peripheral tissues and arterial walls
98 back to the liver, a process known as reverse cholesterol transport (4, 5). Notably, HDL subtypes such as
99 XL_HDL_P, M_HDL_P, M_HDL_C, and M_HDL_CE, indicate different sizes and concentrations of
100 HDL particles, with larger ones being more effective in cholesterol transport (6, 7).

101 HDL is well-known for its cardiovascular benefits (8-10), but its importance in brain health is
102 increasingly recognized. In the brain, cholesterol is not merely a structural component; it is essential for
103 the formation and maintenance of neuronal membranes, synapses, and myelin sheaths (11-13). Indeed,
104 HDL plays a crucial role in cholesterol homeostasis within the brain, facilitating its transport across the
105 blood-brain barrier (BBB) to ensure neurons receive the precise amount needed for optimal function (14-
106 17). Accordingly, by carrying newly synthesized cholesterol from astrocytes to neurons, HDL supports
107 essential lipid-related physiological functions, synaptic maintenance, and plasticity, which are vital for
108 learning and memory (14, 18).

109 In addition to its role in cholesterol transport, HDL exhibited significant anti-inflammatory (19-21) and
110 antioxidant properties (22, 23) that are instrumental in mitigating neuroinflammation and oxidative
111 stress—factors commonly associated with neurocognitive diseases such as mild cognitive impairment
112 (MCI) and Alzheimer’s disease (AD) (24, 25). This means that HDL contributes to neuronal protection
113 and disease progression attenuation by decreasing pro-inflammatory cytokines, reactive oxygen species,
114 and potentially reducing amyloid-beta ($A\beta$) plaque accumulation. Elevated HDL levels are thus correlated
115 with improved cognitive performance and a diminished risk of cognitive decline (19-23).

116 Nonetheless, recent research indicated that HDL’s impact on cognitive function is more nuanced than
117 previously understood. For instance, dysfunctional HDL, resulting from oxidative modifications, can
118 impair neuronal protection and potentially contribute to neurodegenerative conditions (26). Moreover,
119 excessively high HDL levels have been associated with cognitive decline in certain studies, possibly due
120 to intricate interactions with other lipoproteins and inflammatory pathways (27-29). In the context of AD,
121 HDL’s role is complex: While it aids in the clearance of $A\beta$ plaques (30, 31), some HDL subtypes may

122 inadvertently exacerbate disease pathology (32, 33). Consequently, HDL's effects on brain functions are
123 contingent upon its functional state and the broader pathological environment.

124 Tensor-based morphometry (TBM) is a neuroimaging technique that analyzes brain structure by detecting
125 subtle changes in tissue deformation from MRI scans. TBM is particularly effective in longitudinal
126 studies, enabling the tracking of structural changes in the brain over time (34). This capability is crucial
127 for elucidating HDL's impact on brain health across different stages of aging or disease progression.
128 Further, TBM provides regional specificity (35), allowing researchers to precisely identify how HDL
129 affects specific brain regions associated with cognitive functions.

130 Thus far, and to the best of our knowledge, no research has specifically utilized TBM to investigate the
131 impact of HDL on brain structure. Indeed, even though TBM has been extensively utilized to study brain
132 atrophy in neurodegenerative diseases (34, 36-38), it has not yet been used to explore the role of HDL in
133 this context; not to mention that structural atrophy in the brain often correlates with cognitive decline, yet
134 it is not a definitive measure of cognitive impairment on its own.

135 Former research in related areas has utilized neuroimaging techniques like MRI to explore the
136 relationship between cholesterol levels—including HDL—and brain structure. These studies, albeit with
137 conflicting findings, have generally focused on how cholesterol affects brain volume, white matter
138 integrity, and the progression of neurodegenerative diseases like AD. For example, some studies found
139 correlations between lower HDL levels and reduced gray matter volume in brain regions crucial for
140 cognitive function (39-41). This suggests that HDL might play a role in maintaining brain structure,
141 though TBM, which can provide even more detailed structural analysis, has not yet been specifically
142 employed for this purpose. Meanwhile, research using MRI-DTI pointed out that higher HDL levels are
143 associated with better white and grey matter integrity, indicating that HDL can ascribe to preserving the
144 structural health of the brain's communication pathways (42-45).

145 The current study primarily aimed to address conflicting findings regarding HDL's impact on brain
146 structure among patients with MCI by employing TBM—a method that has not yet been utilized for this
147 purpose. This study indeed aimed to investigate longitudinal structural changes in the brain and elucidate
148 how HDL affects specific brain regions associated with neurocognitive disorders.

149 **2. Methods and Materials**

150 The data for this study were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
151 database (<http://adni.loni.usc.edu>), a collaborative project established in 2003 under Dr. Michael W.
152 Weiner. ADNI's goal is to assess whether MRI, PET scans, biological markers, and

153 clinical/neuropsychological evaluations can effectively track the progression of MCI and early AD.
154 Participants, aged 55-90, underwent neuroimaging, lumbar punctures, and regular follow-ups, with
155 detailed inclusion and exclusion criteria outlined elsewhere. Notable exclusions included a Hachinski
156 Ischemic Score above 4, use of non-approved medications, recent changes in allowed medications, a
157 Geriatric Depression Scale score of 6 or higher, and less than six years of education or equivalent work
158 experience. In this study, 93 participants were classified into the MCI group according to ADNI's clinical
159 criteria.

160 **2.1. Cognitive Assessment**

161 The cognitive status of participants was evaluated using standardized assessments like the Alzheimer's
162 Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating (CDR)
163 scale, which are essential tools for monitoring the progression of AD and related conditions.

164 The ADAS-Cog (46, 47) was specifically designed to measure the severity of cognitive symptoms
165 associated with AD. It includes a series of cognitive tests that assess various domains such as memory,
166 language, and praxis (motor coordination). Participants were asked to perform tasks like word recall,
167 object naming, and copying geometric figures. The total score on the ADAS-Cog can range from 0 to 70,
168 with higher scores indicating more severe cognitive impairment. This longitudinal tracking was crucial
169 for understanding how cognitive decline progresses in individuals with MCI or AD (47).

170 The CDR (48) scale was used to assess the overall severity of dementia symptoms across multiple
171 domains, including memory, orientation, judgment, and personal care. The evaluation process involved a
172 semi-structured interview with the participant and an interview with an informant, typically a family
173 member or caregiver. Based on these interviews, a clinician rated each domain on a scale from 0 (no
174 impairment) to 3 (severe impairment). The ratings from each domain were then combined to produce a
175 global CDR score, which classifies participants into categories such as no dementia, very mild dementia,
176 mild dementia, moderate dementia, or severe dementia. The CDR score helps in classifying participants
177 according to the stage of cognitive decline and is used to monitor changes in dementia severity over time
178 (49).

179 **2.2. Neuroimaging Processes**

180 Longitudinal MRI measurements, crucial for detecting neurodegenerative changes in AD and used in
181 clinical trials, led to the development of a robust, bias-free MRI metric for longitudinal studies. The
182 Symmetric Diffeomorphic Image Normalization method was applied to normalize serial scans, producing
183 TBM maps. Summary TBM-Symmetric Normalization (SyN) scores were calculated for each subject at

184 follow-up time points by determining the SyN deformations between each follow-up and baseline scan.
185 The software tools used included MATLAB, ANTs 1.9.x, and SPM5.

186 **2.2.1. Image Preprocessing for Each Individual Image**

187 For each subject, we began with the “N3m” preprocessed datasets and created brain and ventricle masks
188 for each image set. We generated an initial mean image from all N3m images and used SPM5-based
189 mutual information co-registration, iteratively registering each N3m image to the mean. This process
190 continued until the mean image stabilized or reached a maximum of 10 iterations. After the final iteration,
191 all images were co-registered to the base image to ensure accuracy. We then used dilation, hole filling,
192 and subtraction on the co-registered masks to isolate voxels dominated by white matter and cerebrospinal
193 fluid (CSF), fitting Gaussian functions to the intensity spectra and scaling image intensities to standard
194 values.

195 Next, using Aladin, we rigidly co-registered each image to the subject’s baseline image, averaged
196 transformations within the subject, and resampled images and masks into this average space at 1mm
197 isotropic resolution. We formed a new registration target by averaging the resampled images and masks.
198 Affine registration between unregistered images and the average image was performed, followed by
199 resampling into the target space. Finally, we balanced intensities and performed differential bias
200 correction (DBC). Gaussian fits were used to determine white matter and CSF peak intensities for both
201 the mean image and resampled images, with a GM-enhanced intensity spectrum calculated for gray
202 matter. The gray matter, white matter, and CSF intensities were aligned with the mean image using spline-
203 based intensity remapping. DBC was performed using voxels near CSF and white matter peak intensities,
204 creating a dense field via tri-linear interpolation, smoothing it with a 20mm Gaussian kernel, and applying
205 the result to achieve the final preprocessed image.

206 **2.2.2. Longitudinal Measure Free of Bias**

207 High accuracy is often prioritized in warping algorithms, but asymmetric registration between serial scans
208 can introduce bias in longitudinal measurements. We used the SyN algorithm, known for its symmetric
209 registration and high accuracy, to compute deformations between preprocessed scans for each subject. We
210 generated “annualized” log Jacobian maps by dividing log Jacobian voxels by the intrascan time interval.
211 These deformations were applied to create “soft-mean” images, which were then segmented using SPM5,
212 with ROI masks propagated to obtain mean annualized log Jacobian measurements in various ROIs.

213 **2.2.3. Mayo Clinic Patients for Region Selection**

214 In developing longitudinal measurements, statistically significant ROIs are typically identified by
215 analyzing a training set of patients and matched controls to capture neurodegenerative changes. In this
216 study, we selected a training set of 51 AD subjects and 51 PiB-negative CN subjects matched by age,
217 gender, and education, all with longitudinal MRI scans from the Mayo Clinic. To maintain a clean dataset,
218 subjects had to maintain the same clinical diagnosis across both scans, with a baseline age of ≥ 64 years.
219 Using a two-sample t-test, we selected the top 20 regions showing significant differences in GM volumes
220 and longitudinal annualized log Jacobian data, resulting in 31 unique ROIs. Since 30 were GM ROIs
221 (indicating shrinkage) and one was the ventricle (indicating expansion), we inverted the ventricle's log
222 Jacobian determinant before combining it with the GM values.

223 **2.3. Lipoproteins Measurement**

224 In this study, lipoprotein subtypes like HDL were quantified using Nightingale Health's NMR
225 metabolomics platform, which measured over 220 metabolic biomarkers from a single blood sample. This
226 platform provided absolute concentrations of lipids and metabolites, enhancing data interpretability
227 compared to relative measurements from mass spectrometry. Serum samples were prepared and measured
228 between May 31st and June 9th. After thawing, the samples were mixed, centrifuged, and prepared using
229 an automated liquid handler with a specific buffer solution. Measurements were taken with a Bruker
230 AVANCE III HD 500 MHz spectrometer equipped with advanced NMR technology. The NMR data were
231 processed and analyzed using Nightingale's proprietary software, ensuring that metabolite levels were
232 consistent with general population distributions and indicating high sample quality.

233 **2.4. Statistical Analysis**

234 The study utilized R and Python version 3.11 for statistical analysis. Feature selection was performed
235 using F-regression analysis to identify significant metabolites related to brain structural changes.
236 Metabolites with high F-statistics and significant p-values were selected for further analysis. A linear
237 mixed-effects model, implemented in both R and Python, examined the relationship between selected
238 metabolites and TBM imaging data, accounting for random effects at the individual level. Additionally,
239 the study evaluated the association between metabolites and cognitive test scores. Effect sizes were
240 calculated by comparing the R^2 values of each metabolite's model to a baseline model, revealing their
241 contributions to structural brain alterations observed in TBM findings.

242 **3. Results**

243 The study recruited 93 patients diagnosed with MCI. The cohort had a mean age of 65.23 years (± 6.47).
244 Cognitive function was assessed using the ADAS-Cog and CDR scales, with mean scores of 8.31 (± 4.97)

245 and 0.42 (± 0.30), respectively. Among the participants, 54.8% (n=51) were male and 45.2% (n=42) were
 246 female (Table 1).

247 **Table 1.:** Demographic characteristics of the participants.

Number of MCI Subjects		Mean age of the patients	Mean ADAS-Cog score	Mean CDR score
N= 93		65.23 years (± 6.47)	8.31 (± 4.97)	0.42 (± 0.30)
Male	Female			
54.8% (n= 51)	45.2% (n= 42)			

248
 249 The TBM analysis revealed several significant relationships between HDL subtypes and brain structural
 250 changes. For instance, XL_HDL_P exhibited a fixed effect estimate of -0.00145 with a p-value of 0.0293,
 251 indicating a significant impact on brain structure with a modest effect size ($R^2 = 0.0132$). This suggests
 252 that higher levels of XL_HDL_P are associated with reduced brain tissue volume or alterations in brain
 253 density. Similarly, M_HDL_FC_PCT showed a strong fixed effect estimate of -0.00199 and a highly
 254 significant p-value of 0.0016, reflecting a substantial association with brain structural changes, likely
 255 indicating pronounced atrophy or changes in brain shape, as evidenced by a larger effect size of 0.0292.

256 M_HDL_P also demonstrated a significant relationship, with a fixed effect estimate of -0.00138 and a p-
 257 value of 0.0276, which implies a moderate impact on brain structure, potentially related to localized
 258 atrophy or changes in brain density. Likewise, M_HDL_C had a fixed effect estimate of -0.00140 and a p-
 259 value of 0.0254, showing a significant but slightly smaller effect size of 0.0155. M_HDL_CE presented a
 260 fixed effect estimate of -0.00136 with a p-value of 0.0306, indicating a significant association with
 261 modest structural changes or density reductions, with an effect size of 0.0145. Additionally, APOA1 had
 262 a fixed effect estimate of -0.00149 and a p-value of 0.0171, reflecting a notable impact on brain structure,
 263 with an effect size of 0.0181 (Table 2).

264 **Table 2.:** Statistical analysis of HDL subtypes associations with brain structural changes using TBM.

Lipoprotein	Fixed effects					Effect size (R-squared for Generalized Mixed-Effect models)
	Value	P-value	Std ERROR	T-Value	Correlation	R2M
XL_HDL_P	-0.001452114	0.0293	0.000655329	-2.2158546	-0.007	0.01316022
M_HDL_FC_PCT	-0.001993988	0.0016	0.000611075	-3.263083	-0.013	0.02916919
M_HDL_P	-0.00138155	0.0276	0.000616871	-2.2396098	-0.013	0.01568961
M_HDL_C	-0.001398362	0.0254	0.000615041	-2.2736066	-0.018	0.01550452
M_HDL_CE	-0.001356311	0.0306	0.000617285	-2.1972199	-0.019	0.01453341
APOA1	-0.001489386	0.0171	0.000612643	-2.4310835	-0.013	0.01813171

266 Overall, all the lipoproteins analyzed in the TBM study—XL_HDL_P, M_HDL_FC_PCT, M_HDL_P,
267 M_HDL_C, M_HDL_CE, and APOA1—were found to be statistically significant, with p-values below
268 the standard threshold of 0.05. This indicates that each of these lipoproteins has a notable association with
269 brain structural changes, including reductions in brain volume (atrophy), decreases in tissue density, and
270 alterations in brain shape, reflecting their potential impact on brain health.

271 **4. Discussion**

272 The current study, based on our knowledge, is the first to report the use of TBM to investigate the role of
273 HDL subtypes and APOA1 in brain structure and formation. We found that higher levels of XL_HDL_P,
274 M_HDL_FC_PCT, M_HDL_P, M_HDL_C, and M_HDL_CE, as well as APOA1 are linked to reductions
275 in brain volume, decreases in tissue density, and alterations in brain shape. These findings suggested that
276 elevated levels of these lipoproteins may contribute to brain atrophy and other structural changes that are
277 often associated with cognitive decline and neurodegenerative conditions.

278 Consistent with our findings, few studies have also reported that elevated HDL levels may be associated
279 with an increased risk of neurocognitive disorders. For example, a study analyzing data from the ASPREE
280 trial found that older adults with plasma HDL-C levels above 80 mg/dL had a 27% higher risk of
281 developing dementia over an average follow-up of 6.3 years, especially in those aged 75 and older. This
282 association remained significant even after adjusting for factors such as age, sex, and APOE genotype,
283 suggesting that high HDL-C levels could be a risk factor for dementia in older adults (32). Similarly, a
284 study from the China Health and Retirement Longitudinal Study (CHARLS) revealed that higher
285 variability in HDL-C levels was linked to an increased risk of cognitive decline. In a cohort of 5,930
286 participants, those with the highest HDL-C variability had a greater likelihood of cognitive decline
287 compared to those with the lowest variability. The findings suggest that reducing HDL-C variability
288 might help lower the risk of cognitive decline in the general population (28).

289 In addition, recent studies suggest that very high HDL-C levels may increase the risk of dementia, even in
290 younger individuals with comorbidities (50). Elevated HDL has also been linked to poorer cognitive
291 recovery after a stroke, possibly due to metabolic stress (51). In Parkinson's disease, higher HDL levels
292 are associated with cognitive decline, particularly in women. These findings indicate that while HDL is
293 generally considered heart-healthy, its impact on brain health may be more complex and potentially
294 harmful in certain contexts (27).

295 The link between high HDL-C and increased dementia risk is not fully understood. While moderately
296 high HDL-C levels have been associated with better cognitive function, very high HDL-C might be
297 dysfunctional and not reflect effective lipid transport (52). It is also possible that both high HDL-C and

298 dementia could stem from an unrelated pathology. With dementia becoming a growing concern in aging
299 populations, easily measurable markers like HDL-C could be useful, though they may only apply to a
300 small subset of individuals. Hence, further research could clarify the role of high HDL-C in dementia,
301 potentially leading to new insights into its pathogenesis and related health risks.

302 Nonetheless, our findings contrast with those of a recently published meta-analysis of data from 100
303 studies suggesting that HDL-C levels were unrelated to dementia (53). Likewise, several studies
304 collectively highlighted the significant role of HDL-C in cognitive function across various populations,
305 including aging women (54), nonagenarians (55), centenarians (56), and patients with bipolar disorder
306 (57), diabetes mellitus (58), and Parkinson's disease (59). Higher HDL-C levels were consistently
307 associated with better cognitive performance, particularly in areas like memory and learning in such
308 studies. In some cases, low-normal total cholesterol (TC) levels were linked to reduced cognitive function
309 and brain atrophy, suggesting a complex relationship between lipid levels and brain health (60). These
310 findings underscore the protective effects of HDL-C on cognitive function and support further research
311 into its potential as a therapeutic target for neurodegenerative diseases.

312 While the link between high HDL and increased dementia risk remains unclear, several mechanisms may
313 be involved. Dysfunctional HDL at elevated levels could disrupt lipid transport, compromising neuronal
314 membrane integrity and BBB function, which may lead to neuroinflammation and oxidative stress.
315 Additionally, abnormal HDL could impair the clearance of A β peptides, promoting amyloid plaque
316 accumulation in the brain. In short, these processes might contribute to structural brain changes associated
317 with cognitive decline and dementia (26-29, 32, 33).

318 One of the main strengths of this study was its detailed analysis of HDL subtypes, which offered a more
319 nuanced understanding of the relationship between specific lipoproteins and brain structure than studies
320 that only considered overall HDL-C levels. This focus on subtypes allowed the research to explore the
321 intricate ways in which different forms of HDL might influence brain health. Another significant strength
322 was the use of advanced imaging techniques, specifically TBM with the Mayo TBM-SyN pipeline. This
323 approach enabled precise measurement of structural brain changes, which enhanced the reliability and
324 accuracy of the findings. Additionally, the study utilized longitudinal data, with serial MRI scans over
325 time, which strengthened its ability to observe changes in brain structure in relation to HDL levels,
326 providing a more dynamic view of how these factors interplayed over time. The relevance of the study to
327 cognitive decline, particularly in individuals with MCI, was also notable, as it directly addressed a critical
328 area in the understanding of AD progression.

329 However, the study also had some limitations. As an observational study, it could not establish a causal
330 relationship between HDL subtypes and brain atrophy, meaning that the observed associations might have
331 been influenced by other confounding factors. Another limitation was the potential lack of
332 generalizability. Moreover, the study primarily focused on structural brain changes without directly
333 assessing how these changes translated into cognitive or functional outcomes. This left an incomplete
334 picture of the clinical relevance of the findings. Finally, although advanced imaging techniques were
335 used, there was the potential for measurement variability. Differences in MRI scanners, protocols, or
336 image processing methods could have introduced inconsistencies in the TBM scores across participants,
337 potentially affecting the study's results.

338 **5. Conclusion**

339 The study aimed to examine the impact of various HDL subtypes on brain structure in individuals with
340 MCI using TBM. We found that higher levels of specific HDL subtypes, such as XL_HDL_P,
341 M_HDL_FC_PCT, M_HDL_P, M_HDL_C, and M_HDL_CE, as well as APOA1, are significantly
342 associated with lower TBM scores, indicating adverse structural changes like brain atrophy. These
343 findings suggest that elevated levels of these HDL subtypes may contribute to cognitive decline by
344 negatively affecting brain structure in MCI patients.

345

346

347

348

349

350

351

352

353

354

355

356

357

358 **Abbreviations**

359 **HDL:** High-density lipoprotein; **BBB:** blood-brain barrier; **MCI:** mild cognitive impairment; **AD:**
360 Alzheimer's disease; **A β :** amyloid-beta; **TBM:** Tensor-based morphometry; **ADAS-Cog:** Alzheimer's
361 Disease Assessment Scale-Cognitive Subscale; **CDR:** Clinical Dementia Rating; **CSF:** cerebrospinal
362 fluid; **DBC:** differential bias correction.

363

364

365

366

367

368

369 **Declaration sections**

370 **Acknowledgments:** Data used in preparation of this article were obtained from the Alzheimer's Disease
371 Neuroimaging Initiative (ADNI) database (<https://adni.loni.usc.edu/>). As such, the investigators within the
372 ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in
373 analysis or writing of this report. A complete listing of ADNI investigators can be found at:
374 http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

375 **Ethical Approval and Consent to Participate:** This study was conducted using ADNI data. The ADNI
376 study is ethically approved and operated in accordance with the Declaration of Helsinki, 1964.

377 **Consent for Publication:** Not applicable.

378 **Funding:** Not applicable.

379 **Authors' Contributions:** All authors listed have made a substantial, direct, and intellectual contribution to
380 the work, and approved it for publication. A.A., M.A., D.A., A.M.F., and E.R. contributed to developing research
381 ideas and analysis. M.S., M.R., M.M., and A.T. contributed to interpretation of data, writing the draft, and
382 revising it. S.R.P.N., A.H., and H.F. reanalyzed data and contributed to editing draft. N.N., Y.M., M.R., and S.M.M.
383 contributed to writing the draft, and revising it. All authors read and approved the final manuscript.

384 **Availability of Data and Materials:** The data used in this research was obtained from Alzheimer's Disease
385 Neuroimaging Initiative (ADNI) and is available with permission to all researchers.

386 **Competing Interests:** There is no competing interest to be declared.

387

388

389 **References**

- 390 1. von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein
391 revisited: biological functions and clinical relevance. *Eur Heart J*. 2023;44(16):1394-407.
- 392 2. Casula M, Colpani O, Xie S, Catapano AL, Baragetti A. HDL in Atherosclerotic Cardiovascular
393 Disease: In Search of a Role. *Cells* [Internet]. 2021; 10(8).
- 394 3. Morvaridzadeh M, Zoubdane N, Heshmati J, Alami M, Berrougui H, Khalil A. High-Density
395 Lipoprotein Metabolism and Function in Cardiovascular Diseases: What about Aging and Diet Effects?
396 *Nutrients* [Internet]. 2024; 16(5).
- 397 4. Meyer K. Fluorescence Spectroscopic Analysis of Apolipoprotein AI during HDL Particle
398 Modulation: California State University, Long Beach; 2022.
- 399 5. van der Vorst EP. High-density lipoproteins and apolipoprotein A1. Vertebrate and invertebrate
400 respiratory proteins, lipoproteins and other body fluid proteins. 2020:399-420.
- 401 6. Zhao Q, Wang J, Miao Z, Zhang NR, Hennessy S, Small DS, Rader DJ. A Mendelian randomization
402 study of the role of lipoprotein subfractions in coronary artery disease. *eLife*. 2021;10:e58361.
- 403 7. Chary A, Hedayati M. Review of laboratory methods to determine HDL and LDL subclasses and
404 their clinical importance. *Reviews in Cardiovascular Medicine*. 2022;23(4):147.
- 405 8. Perswani P, Ismail SM, Mumtaz H, Uddin N, Asfand M, Khalil ABB, et al. Rethinking HDL-C: an In-
406 Depth narrative review of its role in Cardiovascular Health. *Current Problems in Cardiology*.
407 2024;49(2):102152.
- 408 9. Xiong Y. The role of high-density lipoprotein in cardiovascular disease: benefits, functions, and
409 treatments. *Highlights in Science, Engineering and Technology*. 2022;19:44-50.
- 410 10. Quesada JA, Bertomeu-González V, Orozco-Beltrán D, Cordero A, Gil-Guillén VF, López-Pineda A,
411 et al. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk
412 prediction: A systematic review and meta-analysis. *Clínica e Investigación en Arteriosclerosis (English*
413 *Edition)*. 2023;35(4):165-77.
- 414 11. Ho WY, Hartmann H, Ling SC. Central nervous system cholesterol metabolism in health and
415 disease. *IUBMB life*. 2022;74(8):826-41.
- 416 12. Lee JA, Hall B, Allsop J, Alqarni R, Allen SP, editors. Lipid metabolism in astrocytic structure and
417 function. *Seminars in cell & developmental biology*; 2021: Elsevier.
- 418 13. Vallés AS, Barrantes FJ. The synaptic lipidome in health and disease. *Biochimica et Biophysica*
419 *Acta (BBA)-Biomembranes*. 2022;1864(11):184033.
- 420 14. Turri M, Marchi C, Adorni MP, Calabresi L, Zimetti F. Emerging role of HDL in brain cholesterol
421 metabolism and neurodegenerative disorders. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell*
422 *Biology of Lipids*. 2022;1867(5):159123.
- 423 15. Fung KY, Wang C, Nyegaard S, Heit B, Fairn GD, Lee WL. SR-BI Mediated Transcytosis of HDL in
424 Brain Microvascular Endothelial Cells Is Independent of Caveolin, Clathrin, and PDZK1. *Front Physiol*.
425 2017;8:841.
- 426 16. Sulliman NC, Ghaddar B, Gence L, Patche J, Rastegar S, Meilhac O, Diotel N. HDL biodistribution
427 and brain receptors in zebrafish, using HDLs as vectors for targeting endothelial cells and neural
428 progenitors. *Scientific Reports*. 2021;11(1):6439.
- 429 17. Balazs Z, Panzenboeck U, Hammer A, Sovic A, Quehenberger O, Malle E, Sattler W. Uptake and
430 transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-
431 brain barrier model. *J Neurochem*. 2004;89(4):939-50.
- 432 18. Hottman DA, Chernick D, Cheng S, Wang Z, Li L. HDL and cognition in neurodegenerative
433 disorders. *Neurobiol Dis*. 2014;72 Pt A:22-36.

- 434 19. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory
435 properties of HDL. *Circ Res*. 2004;95(8):764-72.
- 436 20. Fotakis P, Kothari V, Thomas DG, Westerterp M, Molusky MM, Altin E, et al. Anti-inflammatory
437 effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in
438 atherosclerotic plaques. *Arteriosclerosis, thrombosis, and vascular biology*. 2019;39(12):e253-e72.
- 439 21. Chernick D, Zhong R, Li L. The role of HDL and HDL mimetic peptides as potential therapeutics for
440 Alzheimer's disease. *Biomolecules*. 2020;10(9):1276.
- 441 22. Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL):
442 Mechanistic insights into potential clinical benefit. *BBA Clinical*. 2017;8:66-77.
- 443 23. Marsillach J, Adorni MP, Zimetti F, Papotti B, Zuliani G, Cervellati C. HDL Proteome and
444 Alzheimer's Disease: Evidence of a Link. *Antioxidants [Internet]*. 2020; 9(12).
- 445 24. Azargoonjahromi A. Dual role of nitric oxide in Alzheimer's disease. *Nitric Oxide*. 2023;134-
446 135:23-37.
- 447 25. Teleanu DM, Niculescu A-G, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An overview of
448 oxidative stress, neuroinflammation, and neurodegenerative diseases. *International journal of molecular
449 sciences*. 2022;23(11):5938.
- 450 26. Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. Emerging roles for high-density
451 lipoproteins in neurodegenerative disorders. *Biofactors*. 2019;45(5):725-39.
- 452 27. Bakeberg MC, Gorecki AM, Kenna JE, Jefferson A, Byrnes M, Ghosh S, et al. Elevated HDL Levels
453 Linked to Poorer Cognitive Ability in Females With Parkinson's Disease. *Frontiers in Aging Neuroscience*.
454 2021;13.
- 455 28. Luo L, Feng W, Mei M, Tian X, Zhao Y, Liu L, et al. Greater variability in HDL-C was associated with
456 an increased risk of cognitive decline in the middle- and elderly Chinese: A cohort study. *Archives of
457 Gerontology and Geriatrics*. 2024;125:105503.
- 458 29. Liu H, Zou L, Zhou R, Zhang M, Gu S, Zheng J, et al. Long-Term Increase in Cholesterol Is
459 Associated With Better Cognitive Function: Evidence From a Longitudinal Study. *Frontiers in Aging
460 Neuroscience*. 2021;13.
- 461 30. Sparks DL. Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the
462 clearance of Abeta through the liver. *Curr Alzheimer Res*. 2007;4(2):165-9.
- 463 31. Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A, et al. Clearance of beta-amyloid is
464 facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels.
465 *Elife*. 2017;6.
- 466 32. Hussain SM, Robb C, Tonkin AM, Lacaze P, Chong TT-J, Beilin LJ, et al. Association of plasma high-
467 density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy older
468 adults. *The Lancet Regional Health–Western Pacific*. 2024;43.
- 469 33. Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, et al. Low- and High-
470 Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a
471 Large Health Care Plan. *Neurology*. 2023;101(21):e2172-e84.
- 472 34. An M. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer'.
- 473 35. Colom R, Hua X, Martínez K, Burgaleta M, Román FJ, Gunter JL, et al. Brain structural changes
474 following adaptive cognitive training assessed by Tensor-Based Morphometry (TBM). *Neuropsychologia*.
475 2016;91:77-85.
- 476 36. Seyedmirzaei H, Salmannezhad A, Ashayeri H, Shushtari A, Farazinia B, Heidari MM, et al.
477 Growth-associated protein 43 and tensor-based morphometry indices in mild cognitive impairment.
478 *Neuroinformatics*. 2024:1-12.
- 479 37. Wang Y, Zhao R, Zhu D, Fu X, Sun F, Cai Y, et al. Voxel-and tensor-based morphometry with
480 machine learning techniques identifying characteristic brain impairment in patients with cervical
481 spondylotic myelopathy. *Frontiers in Neurology*. 2024;15:1267349.

- 482 38. Huang H, Zheng S, Yang Z, Wu Y, Li Y, Qiu J, et al. Voxel-based morphometry and a deep learning
483 model for the diagnosis of early Alzheimer's disease based on cerebral gray matter changes. *Cerebral*
484 *Cortex*. 2023;33(3):754-63.
- 485 39. Yang FN, Stanford M, Jiang X. Low Cholesterol Level Linked to Reduced Semantic Fluency
486 Performance and Reduced Gray Matter Volume in the Medial Temporal Lobe. *Frontiers in Aging*
487 *Neuroscience*. 2020;12.
- 488 40. Ward MA, Bendlin BB, McLaren DG, Hess TM, Gallagher CL, Kastman EK, et al. Low HDL
489 Cholesterol is Associated with Lower Gray Matter Volume in Cognitively Healthy Adults. *Front Aging*
490 *Neurosci*. 2010;2.
- 491 41. Zhang C, Yang Y, Zhu D-m, Zhao W, Zhang Y, Zhang B, et al. Neural correlates of the association
492 between depression and high density lipoprotein cholesterol change. *Journal of Psychiatric Research*.
493 2020;130:9-18.
- 494 42. Johnson NF, Gold BT, Ross D, Bailey AL, Clasey JL, Gupta V, et al. Non-fasting High-Density
495 Lipoprotein Is Associated With White Matter Microstructure in Healthy Older Adults. *Frontiers in Aging*
496 *Neuroscience*. 2019;11.
- 497 43. Crisby M, Bronge L, Wahlund L-O. Low levels of high density lipoprotein increase the severity of
498 cerebral white matter changes: implications for prevention and treatment of cerebrovascular diseases.
499 *Current Alzheimer Research*. 2010;7(6):534-9.
- 500 44. Ward MA, Bendlin BB, McLaren DG, Hess TM, Gallagher CL, Kastman EK, et al. Low HDL
501 cholesterol is associated with lower gray matter volume in cognitively healthy adults. *Frontiers in aging*
502 *neuroscience*. 2010;2:29.
- 503 45. Warstadt NM, Dennis EL, Jahanshad N, Kohannim O, Nir TM, McMahon KL, et al. Serum
504 cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure.
505 *Neurobiology of aging*. 2014;35(11):2504-13.
- 506 46. Nogueira J, Freitas S, Duro D, Tabuas-Pereira M, Guerreiro M, Almeida J, Santana I. Alzheimer's
507 Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Normative Data for the Portuguese
508 Population. *Acta medica portuguesa*. 2018;31(2).
- 509 47. Mohs RC. The Alzheimer's disease assessment scale. *International psychogeriatrics*.
510 1996;8(2):195-203.
- 511 48. Hughes CP, Berg L, Danziger W, Coben LA, Martin RL. A new clinical scale for the staging of
512 dementia. *The British journal of psychiatry*. 1982;140(6):566-72.
- 513 49. Khan TK. Chapter 2 - Clinical Diagnosis of Alzheimer's Disease. In: Khan TK, editor. *Biomarkers in*
514 *Alzheimer's Disease*: Academic Press; 2016. p. 27-48.
- 515 50. Kjeldsen EW, Thomassen JQ, Juul Rasmussen I, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-
516 Schmidt R. Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic
517 studies. *Cardiovasc Res*. 2022;118(5):1330-43.
- 518 51. Newman GC, Bang H, Hussain SI, Toole JF. Association of diabetes, homocysteine, and HDL with
519 cognition and disability after stroke. *Neurology*. 2007;69(22):2054-62.
- 520 52. von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein
521 revisited: biological functions and clinical relevance. *European heart journal*. 2023;44(16):1394-407.
- 522 53. Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J.
523 Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. *Brain Sci*. 2020;10(6).
- 524 54. Bates KA, Sohrabi HR, Rainey-Smith SR, Weinborn M, Bucks RS, Rodrigues M, et al. Serum high-
525 density lipoprotein is associated with better cognitive function in a cross-sectional study of aging
526 women. *International Journal of Neuroscience*. 2017;127(3):243-52.
- 527 55. Pancani S, Sofi F, Cecchi F, Macchi C. HDL Cholesterol Is Independently Associated with Cognitive
528 Function in Males But Not in Females within a Cohort of Nonagenarians: The Mugello Study. *The Journal*
529 *of nutrition, health and aging*. 2019;23(6):552-7.

- 530 56. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N. Plasma HDL Levels Highly
531 Correlate With Cognitive Function in Exceptional Longevity. *The Journals of Gerontology: Series A.*
532 2002;57(11):M712-M5.
- 533 57. Hui L, Yin XL, Chen J, Yin XY, Zhu HL, Li J, et al. Association between decreased HDL levels and
534 cognitive deficits in patients with bipolar disorder: a pilot study. *International Journal of Bipolar*
535 *Disorders.* 2019;7(1):25.
- 536 58. Wu Y, Tan KC, Shiu SW, Luo Y, Shi L, Kwok TC. Cholesterol efflux capacity of high-density
537 lipoprotein was not associated with cognitive decline and brain structures in older people with diabetes
538 mellitus. *J Diabetes Investig.* 2022;13(11):1873-80.
- 539 59. Yang FN, Stanford M, Jiang X. Low Cholesterol Level Linked to Reduced Semantic Fluency
540 Performance and Reduced Gray Matter Volume in the Medial Temporal Lobe. *Front Aging Neurosci.*
541 2020;12:57.
- 542 60. Crichton GE, Elias MF, Davey A, Sullivan KJ, Robbins MA. Higher HDL Cholesterol Is Associated
543 with Better Cognitive Function: the Maine-Syracuse Study. *Journal of the International*
544 *Neuropsychological Society.* 2014;20(10):961-70.

545